Neurocrine Biosciences (NBIX) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.13 -0.33%
Revenue Growth %: +30.8%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +30.8%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.64, $0.05 better than the analyst estimate of $0.59. Revenue for the quarter came in at $296 million versus the consensus estimate of $296.65 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Braze stock tumbles 10% on weak third quarter EPS guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
